



Brief presentation of MLC



Diagnostics of human health and the environment

The first flagship product **CGM Fly**

CGM «Fly» provides continuous monitoring of blood glucose levels.



Number of countries: Number of participants:

📍 **171**

👤 **50 000**



**The MLC team is
an international
community**

Management:



Ivan Saltanov — Founder, CEO.



Elena Saltanova — Co-Founder, CVO.



Maxim Kolomiets — Co-Founder, CFO.



Sergey Melenkov — Co-Founder, CTO.



Marina Tmenova — Co-Founder, Editor-in-Chief.

Collaboration:



ARTLEBEDEV

Artemy Lebedev Studio — Industrial design of the CGM device

FRAXIS

FRAXIS - Development of CGM's electronic components, software



MegaResearch — number one marketing agency in Russia


More than 100 people from 15 teams are already engaged in developing the product: IT development and software, electronics and circuitry, design and modeling, research teams from Russia, China, and full-time employees of the laboratory.


The mission of the MLC project is the CGM Fly product

Making the CGM device available worldwide to diagnose diabetes at early stages, maintain high quality of life for people already diagnosed with the disease, and improve physical performance within the sports sector.

Our humanitarian mission aims to increase human life expectancy.

By developing the project, on the one hand, you give everyone in need the opportunity to get this product, on the other hand, you gain financial stability.





Our own laboratory



Patents and research

7 patents obtained!




11 more applications are in the works in 2024.



Current stage

— 7 из 17



- Net funding required (no fundraising costs): \$ 2 million.
- Distribution: **15% of the company's shares.**
- The main value of the stage: **Building our own prototype, certification, technology refinement.**
- Source of funding: **private small and medium-sized investments attracted worldwide. Business angels, venture capital funds and accelerators specializing in Pre-Seed stage.**

Outlook for the CGM market



The market of continuous glucose monitoring systems has a high growth potential!



MLC commissioned a market research on **CGM** application in the world, as well as an analysis of the prospects and development of the market by **MegaResearch**, a leading marketing agency in Russia.



The potential market volume is **16.7 billion** units. The actual sales volume of **CGM** systems is **0.5%** of the potential one.




Experts forecast an average annual growth in consumption of CGM devices to be **15%**.



By 2045, the market will grow from 98.6 to **2,343.4 million** devices per year (23.8 times), which will be equivalent to the growth from USD **10,953.3 million to USD 233,127.7 million** (21.3 times). At the same time, the supply of devices will amount to **11.5%** of the total number of diabetic patients.

Transparent legal framework



Growth prospects for MLC's assets



Total number of shares: **20** billion

Total number of shares for sale: **10** billion

Number of shares sold and reserved as of June 2024: **5** billion

Seeking to capitalize:

1 MLC investment share = 1 MLC share =
= **1** dollar

**Standing with MLC
for a green future
and healthy life!**

